tetano
Editor, Senior Moderator
J Virol Methods. 2014 May 29. pii: S0166-0934(14)00208-0. doi: 10.1016/j.jviromet.2014.05.016. [Epub ahead of print]
Prophylaxis and therapy of pandemic H1N1 virus infection using egg yolk antibody.
Yuan YE1, Junlin W1, Zhao S2, Zhang K1, Yingliang Z3.
Author information
Abstract
Influenza A virus infects the human respiratory system and causes acute and fatal pulmonary diseases. The emergence of drug-resistant viral strains highlights the need for alternative therapeutic approaches. In this work, IgY antibody was raised in immunized laying hens, and its antiviral activity was evaluated in the context of passive immunization. With inactivated whole H1N1 virus, high-titer IgY antibody 9.18mg/mL egg yolk was induced by the eighth week after immunization. Western blotting and the hemagglutination inhibition (HI) test demonstrated that the IgY antibody could specifically bind the neuraminidase and hemagglutinin of the H1N1 virus. In the plaque reduction assay, the IgY antibody reduced the H1N1 viral infection in MDCK (Madin-Darby canine kidney) cells. In a mouse model, the anti-H1N1 IgY antibody exhibited in vivo protection by reducing the infectious titer of the virus in the lung while maintaining the weight and normal structure of the lung tissue. Additionally, the anti-H1N1 IgY antibody exhibited protective activity comparable to the neuraminidase inhibitor oseltamivir. These results demonstrated that IgY can be easily produced and can offers an effective alternative approach for influenza control.
Copyright ? 2014. Published by Elsevier B.V.
KEYWORDS:
Antiviral; Egg yolk antibody (IgY); Immunoprophylaxis; Immunotherapy; Pandemic H1N1 influenza virus
PMID:
24880066
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24880066
Prophylaxis and therapy of pandemic H1N1 virus infection using egg yolk antibody.
Yuan YE1, Junlin W1, Zhao S2, Zhang K1, Yingliang Z3.
Author information
Abstract
Influenza A virus infects the human respiratory system and causes acute and fatal pulmonary diseases. The emergence of drug-resistant viral strains highlights the need for alternative therapeutic approaches. In this work, IgY antibody was raised in immunized laying hens, and its antiviral activity was evaluated in the context of passive immunization. With inactivated whole H1N1 virus, high-titer IgY antibody 9.18mg/mL egg yolk was induced by the eighth week after immunization. Western blotting and the hemagglutination inhibition (HI) test demonstrated that the IgY antibody could specifically bind the neuraminidase and hemagglutinin of the H1N1 virus. In the plaque reduction assay, the IgY antibody reduced the H1N1 viral infection in MDCK (Madin-Darby canine kidney) cells. In a mouse model, the anti-H1N1 IgY antibody exhibited in vivo protection by reducing the infectious titer of the virus in the lung while maintaining the weight and normal structure of the lung tissue. Additionally, the anti-H1N1 IgY antibody exhibited protective activity comparable to the neuraminidase inhibitor oseltamivir. These results demonstrated that IgY can be easily produced and can offers an effective alternative approach for influenza control.
Copyright ? 2014. Published by Elsevier B.V.
KEYWORDS:
Antiviral; Egg yolk antibody (IgY); Immunoprophylaxis; Immunotherapy; Pandemic H1N1 influenza virus
PMID:
24880066
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24880066